
AstraZeneca Bets $1.5 Billion on AI ‘Virtual Human’ to Discover New Heart and Liver Disease Drugs
AstraZeneca has signed a deal worth up to $1.5 billion with biotechnology company Insitro to use artificial intelligence (AI) to discover new treatments for liver and heart diseases. Announced on October 15, 2026, the partnership will use Insitro’s “Virtual Human” … Continue reading →















